Department of Pulmonology, University of Health Sciences Yedikule Pulmonary Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye.
Department of Thoracic Surgery, Faculty of Medicine, Marmara University, İstanbul, Türkiye.
Anatol J Cardiol. 2023 Mar;27(3):153-159. doi: 10.14744/AnatolJCardiol.2022.2392.
Chronic thromboembolic pulmonary hypertension is a condition that occurs after mechanical obstruction of the pulmonary arteries by thrombus. Since the frequency and demographics of chronic thromboembolic pulmonary hypertension differ between countries, it is thought that genetic factors may play a role in its development. The aim of this study is to reveal the status of VKORC1, CYP2C93, CYP2C97, and fibrinogen-Aα THR312ALA gene polymorphisms in chronic thromboembolic pulmonary hypertension patients in Turkey.
In this prospective cross-sectional study, a total of 46 chronic thromboembolic pulmonary hypertension patients and 106 healthy volunteers were included. Polymerase chain reaction-restriction fragment length polymorphism method was used to determine candidate gene polymorphisms for chronic thromboembolic pulmonary hypertension. The general population parameters of each locus were calculated, and the relationship between dominant, codominant, and recessive genotype models and chronic thromboembolic pulmonary hypertension was analyzed.
For the fibrinogen-Aα gene, those with the THR/THR genotype were found to have a 13.51 (95% CI: 2.688-33.333) times less susceptibility rate to the disease than those with the ALA/THR genotype, the susceptibility of THR/ALA genotype to the disease was 5.026 (95% CI: 1.774-14.242) times more than those with ALA/ALA genotype. There was no difference between patient groups for VKORC1, CYP2C93 genes (P >.05). Since the CYP2C97 patient group was monomorphic for the ILE allele, the patient/control odds ratio and 95% CI could not be calculated.
This study shows that there is an association between the fibrinogen-Aα gene ALA polymorphism at the amino acid position of 312 and the development of chronic thromboembolic pulmonary hypertension, but not between the CYP2C9 and VKORC1 gene polymorphisms.
慢性血栓栓塞性肺动脉高压是一种由于血栓导致肺动脉机械阻塞而发生的疾病。由于慢性血栓栓塞性肺动脉高压在各国的发生频率和人口统计学特征不同,因此认为遗传因素可能在其发病机制中起作用。本研究旨在揭示土耳其慢性血栓栓塞性肺动脉高压患者 VKORC1、CYP2C93、CYP2C97 和纤维蛋白原 Aα THR312ALA 基因多态性的状况。
在这项前瞻性病例对照研究中,共纳入 46 例慢性血栓栓塞性肺动脉高压患者和 106 例健康志愿者。采用聚合酶链反应-限制性片段长度多态性方法确定慢性血栓栓塞性肺动脉高压候选基因多态性。计算每个基因座的一般人群参数,并分析显性、共显性和隐性基因型模型与慢性血栓栓塞性肺动脉高压的关系。
对于纤维蛋白原 Aα 基因,与 THR/THR 基因型相比,THR/THR 基因型对疾病的易感性降低 13.51 倍(95%CI:2.688-33.333),THR/ALA 基因型对疾病的易感性增加 5.026 倍(95%CI:1.774-14.242)与 ALA/ALA 基因型相比。VKORC1、CYP2C93 基因在患者组和对照组之间无差异(P>.05)。由于 CYP2C97 患者组的 ILE 等位基因呈单态性,无法计算患者/对照比值比及其 95%CI。
本研究表明,纤维蛋白原 Aα 基因 312 位氨基酸位置的 ALA 多态性与慢性血栓栓塞性肺动脉高压的发生有关,但 CYP2C9 和 VKORC1 基因多态性与慢性血栓栓塞性肺动脉高压无关。